Rectal microbicide research takes giant leap forward with groundbreaking educational video

December 17, 2012

International Rectal Microbicide Advocates (IRMA), the Population Council, and the Microbicide Trials Network (MTN) today released a collaborative video project called "The Rectal Revolution Is Here: An Introduction to Rectal Microbicide Clinical Trials." The jointly produced video, the first of its kind, is designed to educate communities affected by HIV about rectal microbicide development and the importance of participating in clinical trials to help speed the search for new HIV prevention options.

"The Rectal Revolution will be an excellent tool for education and recruitment for MTN-017, the first-ever Phase II safety trial of a rectal microbicide planned to launch soon. The video will be particularly useful because it's not protocol-specific and can be used in future rectal microbicide trials as well," said Clare Collins, MTN associate director of communications and external relations and video co-producer.

"There is an engaging mixture of animation and live action with beautiful footage from Thailand, South Africa, Peru, and the United States," Collins continued, "and we showcase interviews with scientists, advocates, and an exceptional rectal microbicide trial participant, Rig Rush, who is both eloquent and entertaining as he shares his personal experience as a study volunteer."

Produced by Paw Print Productions of Cape Town, South Africa, the video is available for viewing now on YouTube in English, Spanish, and Thai.

"This educational video is a groundbreaking tool to recruit volunteers and educate public health leaders for what may be one of the most promising new methods to fight HIV," said co-producer Barbara Friedland, associate in the HIV and AIDS program at the Population Council. "It was developed through an intense consultative process to ensure accuracy and relevance to the communities where this video will be shown," she said.

"We wanted the video to be educational and engaging, and to encourage audiences to get involved in efforts to prevent HIV," Friedland continued."So we worked with an advisory committee comprising staff at rectal microbicide trial sites, scientists, advocates, and other community experts to develop the script. We screened 'rough cuts' of the video with 80 professionals in the field and pre-tested it in 13 focus group discussions with over 100 gay men and transgender women in Thailand, South Africa, Peru, and the United States," she said.

"The insights and wisdom these individuals shared with us were absolutely critical to shaping the final version of the video," said Friedland.

Major funding and support for the project was generously provided by the MAC AIDS Fund, the MTN, and the Population Council, through a grant from the Swedish Ministry of Foreign Affairs.

The video debut precedes the soon-to-be launched landmark study being conducted by MTN to test a reduced-glycerin formulation of tenofovir gel among gay men, other men who have sex with men, and transgender women for safety and acceptability. MTN-017 is not only the first-ever Phase II study of a rectal microbicide, it is also the first time rectal microbicide research is expanding outside the United States and going global, with sites in Thailand, South Africa, Peru, and Puerto Rico.

"IRMA and the Population Council enthusiastically support the start of MTN-017," said Jim Pickett, IRMA chair. "The 186 individuals who will volunteer for the trial will more than double the total number of people who have participated in rectal microbicide clinical trials to date. The study will mark a giant leap forward for the field of rectal microbicides and will set the stage for future large-scale efficacy trials," he said.

Pickett continued, "the day we have a safe, effective, and acceptable rectal microbicide as a much-needed HIV prevention option for people who engage in anal intercourse is within our sights--these are truly revolutionary times and we couldn't be more energized."

Learn more about the MTN-017 trial here: http://www.mtnstopshiv.org/news/studies/mtn017
-end-
IRMA, the Population Council, and MTN encourage HIV prevention advocates and community educators to screen The Rectal Revolution Is Here in their own workshops and sensitization sessions and to share it widely. To receive a copy of the video in English, Spanish, or Thai, please contact IRMA at rectalmicro@gmail.com.

Editorial notes:

Currently in development, microbicides are products (gels, lubricants, films) that could be applied in the rectum or the vagina to reduce the risk of HIV infection.

Unprotected anal intercourse is 10 to 20 times more likely to result in HIV infection compared to unprotected vaginal intercourse. Unprotected anal intercourse--a common human behavior--is a significant driver in the global HIV epidemic among gay men and transgender women as well as among heterosexuals.

IRMA, based at AIDS Foundation of Chicago, is a global network of more than 1,000 advocates, scientists, policy makers, and funders from six continents working together to advance a robust rectal microbicide research and development agenda. The "bottom line in HIV prevention," IRMA addresses the institutional, socio-cultural, and political stigma around the public health need for rectal microbicide research, and advocates to increase funding and commitment within this field of inquiry.

The Population Council confronts critical health and development issues--from stopping the spread of HIV to improving reproductive health and ensuring that young people lead full and productive lives. Through biomedical, social science, and public health research in 50 countries, we work with our partners to deliver solutions that lead to more effective policies, programs, and technologies that improve lives around the world. Established in 1952 and headquartered in New York, the Council is a nongovernmental, nonprofit organization governed by an international board of trustees.

International Rectal Microbicide Advocates

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.